Intermittent Screening and Treatment versus Intermittent Preventive Treatment of Malaria in Pregnancy: A Randomised Controlled Non-Inferiority Trial

被引:91
|
作者
Tagbor, Harry [1 ]
Bruce, Jane [3 ]
Agbo, Mitchell [2 ]
Greenwood, Brian [3 ]
Chandramohan, Daniel [3 ]
机构
[1] Kwame Nkrumah Univ Sci & Technol, Sch Med Sci, Dept Community Hlth, Kumasi, Ghana
[2] Juaben Govt Hosp, Juaben, Ashanti, Ghana
[3] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England
来源
PLOS ONE | 2010年 / 5卷 / 12期
关键词
SULFADOXINE-PYRIMETHAMINE RESISTANCE; WOMEN; DIAGNOSIS; EFFICACY; THERAPY; BURDEN; KENYA;
D O I
10.1371/journal.pone.0014425
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: The effectiveness of intermittent preventive treatment of malaria in pregnancy (IPTp) may be compromised by the spread of resistance to sulphadoxine/pyrimethamine (SP) across Africa. But little informtion exists on alternative drugs for IPTp or alternative strategies for the prevention of malaria in pregnancy. Therefore, we have investigated whether screening with a rapid diagnostic test and treatment of those who are positive (IST) at routine antenatal clinic attendances is as effective and as safe as SP-IPTp in pregnant women. Methods and Findings: During antenatal clinic sessions in six health facilities in Ghana held between March 2007 and September 2007, 3333 pregnant women who satisfied inclusion criteria were randomised into three intervention arms (1) standard SP-IPTp, (2) IST and treatment with SP or (3) IST and treatment with amodiaquine+artesunate (AQ+AS). All women received a long-lasting insecticide treated net. Study women had a maximum of three scheduled follow-up visits following enrolment. Haemoglobin concentration and peripheral parasitaemia were assessed between 36 and 40 weeks of gestation. Birth weight was measured at delivery or within 72 hours for babies delivered at home. Parasite prevalence at enrolment in primigravidae and in multigravidae was 29.6% and 10.2% respectively. At 36-40 weeks of gestation the prevalence of asymptomatic parasitaemia was 12.1% in study women overall and was very similar in all treatment groups. The risk of third trimester severe anaemia or low birth weight did not differ significantly between the three treatment groups regardless of gravidity. IST with AQ+AS or SP was not inferior to SP-IPTp in reducing the risk of low birth weight (RD = -1.17[95% CI; -4.39-1.02] for IST-SP vs. SP-IPTp and RD = 0.78[95% CI; -2.11-3.68] for IST-AQAS vs. SP-IPTp); third trimester severe anaemia (RD = 0.29[95% CI; -0.69-1.30] for IST-SP vs. SP-IPTp and RD = -0.36[95% CI;-1.12-0.44] for IST-AQAS vs. SP-IPTp). Conclusion: The results of this study suggest that in an area of moderately high malaria transmission, IST with SP or AS+AQ may be a safe and effective strategy for the control of malaria in pregnancy. However, it is important that these encouraging findings are confirmed in other geographical areas and that the impact of IST on placental malaria is investigated.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] 'Intermittent' versus 'continuous' ScvO2 monitoring in children with septic shock: a randomised, non-inferiority trial
    Sankar, Jhuma
    Singh, Man
    Kumar, Kiran
    Sankar, M. Jeeva
    Kabra, Sushil Kumar
    Lodha, Rakesh
    INTENSIVE CARE MEDICINE, 2020, 46 (01) : 82 - 92
  • [42] ‘Intermittent’ versus ‘continuous’ ScvO2 monitoring in children with septic shock: a randomised, non-inferiority trial
    Jhuma Sankar
    Man Singh
    Kiran Kumar
    M. Jeeva Sankar
    Sushil Kumar Kabra
    Rakesh Lodha
    Intensive Care Medicine, 2020, 46 : 82 - 92
  • [43] Targeting of intermittent preventive treatment for malaria
    Steketee, Richard W.
    Slutsker, Laurence
    LANCET INFECTIOUS DISEASES, 2012, 12 (03): : 168 - 169
  • [44] Intermittent preventive treatment for malaria in infants
    Esu, Ekpereonne B.
    Oringanje, Chioma
    Meremikwu, Martin M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (12):
  • [45] Intermittent preventive treatment of malaria in infancy
    McGready, Rose
    LANCET, 2009, 374 (9700): : 1478 - 1480
  • [46] Intermittent preventive treatment for malaria in infants
    Esu, Ekpereonne B.
    Oringanje, Chioma
    Meremikwu, Martin M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (07):
  • [47] Impact of intermittent preventive treatment of malaria in pregnancy with dihydroartemisinin-piperaquine versus sulfadoxine-pyrimethamine on the incidence of malaria in infancy: a randomized controlled trial
    Abel Kakuru
    Prasanna Jagannathan
    Richard Kajubi
    Teddy Ochieng
    Harriet Ochokoru
    Miriam Nakalembe
    Tamara D. Clark
    Theodore Ruel
    Sarah G. Staedke
    Daniel Chandramohan
    Diane V. Havlir
    Moses R. Kamya
    Grant Dorsey
    BMC Medicine, 18
  • [48] Impact of intermittent preventive treatment of malaria in pregnancy with dihydroartemisinin-piperaquine versus sulfadoxine-pyrimethamine on the incidence of malaria in infancy: a randomized controlled trial
    Kakuru, Abel
    Jagannathan, Prasanna
    Kajubi, Richard
    Ochieng, Teddy
    Ochokoru, Harriet
    Nakalembe, Miriam
    Clark, Tamara D.
    Ruel, Theodore
    Staedke, Sarah G.
    Chandramohan, Daniel
    Havlir, Diane, V
    Kamya, Moses R.
    Dorsey, Grant
    BMC MEDICINE, 2020, 18 (01)
  • [49] Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial
    Jagannathan, Prasanna
    Kakuru, Abel
    Okiring, Jaffer
    Muhindo, Mary K.
    Natureeba, Paul
    Nakalembe, Miriam
    Opira, Bishop
    Olwoch, Peter
    Nankya, Felistas
    Ssewanyana, Isaac
    Tetteh, Kevin
    Drakeley, Chris
    Beeson, James
    Reiling, Linda
    Clark, Tamara D.
    Rodriguez-Barraquer, Isabel
    Greenhouse, Bryan
    Wallender, Erika
    Aweeka, Francesca
    Prahl, Mary
    Charlebois, Edwin D.
    Feeney, Margaret E.
    Havlir, Diane V.
    Kamya, Moses R.
    Dorsey, Grant
    PLOS MEDICINE, 2018, 15 (07)
  • [50] Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial
    Maertens, Johan A.
    Rahav, Galia
    Lee, Dong-Gun
    Ponce-de-Leon, Alfredo
    Ramirez Sanchez, Isabel Cristina
    Klimko, Nikolay
    Sonet, Anne
    Haider, Shariq
    Diego Velez, Juan
    Raad, Issam
    Koh, Liang-Piu
    Karthaus, Meinolf
    Zhou, Jianying
    Ben-Ami, Ronen
    Motyl, Mary R.
    Han, Seongah
    Grandhi, Anjana
    Waskin, Hetty
    LANCET, 2021, 397 (10273): : 499 - 509